AI Article Synopsis
- The study compared the effectiveness and safety of combining traditional Chinese medicines (TCMs) with paclitaxel chemotherapy versus using paclitaxel chemotherapy alone for treating gastric cancer.
- Results from 14 randomized controlled trials with 1,109 participants showed that combining TCMs significantly improved tumor response rates and quality of life while reducing common side effects like neutropenia and nausea.
- The authors concluded that while the combination treatment appears beneficial, more large and well-designed trials are needed to further confirm its efficacy and safety.
Article Abstract
This study aimed to compare the efficacy and safety of traditional Chinese medicines (TCMs) combined with paclitaxel-based chemotherapy and paclitaxel-based chemotherapy alone for gastric cancer treatment. Literature searches (up to September 25, 2019) were performed using the Cochrane Library, EMBASE, PubMed, Chinese Science and Technology Journals (CQVIP), Wanfang, and China Academic Journals (CNKI) databases. Data from 14 randomized controlled trials (RCTs), with 1,109 participants, were included. The results indicated that, compared with paclitaxel-based chemotherapy alone, the combination of TCMs and paclitaxel-based chemotherapy significantly improved the tumor response rate (TRR; RR: 1.39; 95% CI: 1.24-1.57; < 0.001, = 12%), increased the quality of life based on the Karnofsky Performance Scale score (RR: 1.53; 95% CI: 1.19-1.96; < 0.001, = 0%), and reduced the side effects, such as neutropenia (RR: 0.68; 95% CI: 0.55-0.84; < 0.001, = 44%), leukopenia (RR: 0.69; 95% CI: 0.54-0.90; < 0.01, = 40%), thrombocytopenia (RR: 0.66; 95% CI: 0.46-0.96; < 0.05, = 32%), and nausea and vomiting (RR: 0.50; 95% CI: 0.32-0.80; < 0.01, = 85%). Hepatic dysfunction (RR: 0.63; 95% CI: 0.33-1.20; = 0.16, = 0%), neurotoxicity (RR: 0.64; 95% CI: 0.26-1.55; = 0.32, = 0%), and anemia (RR: 0.65; 95% CI: 0.40-1.04; = 0.07, = 0%) were similar between the two groups. Evidence from the meta-analysis suggested that compared with paclitaxel-based chemotherapy alone, the combination of TCMs and paclitaxel-based chemotherapy may increase the TRR, improve quality of life, and reduce multiple chemotherapy-related side effects in gastric cancer patients. Additional rigorously designed large RCTs are required to confirm the efficacy and safety of this treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056897 | PMC |
| http://dx.doi.org/10.3389/fphar.2020.00132 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RSL3 induces ferroptosis by activating the NF-κB signalling pathway to enhance the chemosensitivity of triple-negative breast cancer cells to paclitaxel.
Sci Rep
January 2025
Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
Chemotherapy resistance in triple-negative breast cancer (TNBC) leads to poor therapeutic effects and a poor prognosis. Given that paclitaxel-based chemotherapy is the main treatment method for TNBC, enhancing its chemosensitivity has been a research focus. Induced ferroptosis of tumour cells has been proven to increase chemosensitivity, but its ability to sensitize TNBC cells to paclitaxel (PTX) is unknown.
View Article and Find Full Text PDFEfficacy and Safety of Paclitaxel-Based PD-1/PD-L1 Immunotherapies for Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis.
Clin Med Insights Oncol
December 2024
Center of Clinical Evaluation and Analysis, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Background: Triple negative breast cancer (TNBC) is a deadly subtype of breast cancer with limited treatment options. Currently, programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have become the first choice for breast cancer immunotherapies. Despite paclitaxel being considered a cornerstone drug in breast cancer treatment, the effectiveness, safety, and optimal drug selection for its combination with PD-1/PD-L1 inhibitors remain uncertain.
View Article and Find Full Text PDFGenetic Polymorphisms of DNA Repair Genes and their Influence on Paclitaxel based Chemotherapy Induced Toxicity Reactions in Breast Cancer Patients.
Asian Pac J Cancer Prev
December 2024
Department of Oncology, Krishna Vishwa Vidyapeeth "Deemed to be University", Taluka-Karad, Dist- Satara, Pin-415 539, (Maharashtra) India.
Background: Systemic chemotherapy constitutes an indispensable component of breast cancer (BC) management, where therapeutic drug combinations such as anthracyclines, platinum compounds, and taxanes form the cornerstone of standard treatment protocols. Although DNA repair genes are pivotal in cancer susceptibility, their specific roles in mediating acute or chronic toxicity outcomes induced by chemotherapy remain undetermined. Consequently, this study was planned to elucidate the impact of polymorphisms in base excision repair (BER) genes, including XRCC1, XRCC2, XRCC3, APE1, and hOGG1, on treatment response and toxicity outcomes in BC patients undergoing paclitaxel and doxorubicin-based chemotherapy within an Indian population.
View Article and Find Full Text PDFSintilimab Combined with Nanoparticle Albumin-Bound Paclitaxel-Based Chemotherapy in Severe Locally Advanced or Metastatic Squamous NSCLC Showed Good Efficacy and Safety: A Pilot Retrospective Analysis.
Int J Nanomedicine
November 2024
Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Introduction: Squamous non-small cell lung carcinoma (sqNSCLC) is associated with a poorer prognosis and limited treatment options. Sintilizumab combined with chemotherapy is used as first-line treatment for advanced sqNSCLC. However, the efficacy and safety of sintilimab combined with nanoparticle albumin-bound paclitaxel-based chemotherapy for severe squamous NSCLC remain to be unknown in clinical studies.
View Article and Find Full Text PDFPrediction of Health Status in Patients Undergoing Lower Extremity Intervention for Claudication.
Ann Vasc Surg
January 2025
Vascular Medicine Outcomes Program, Section of Cardiology, Department of Internal Medicine, Yale University, New Haven, CT. Electronic address:
Article Synopsis
- The study investigates predictors of health status outcomes in patients with lower extremity peripheral artery disease (PAD) who have undergone a specific vascular intervention, aiming to improve patient care based on these predictors.
- It analyzed 468 participants and assessed 59 baseline characteristics to identify the most important factors influencing health status one year post-intervention using a machine learning model.
- Key findings indicate that comorbidities, particularly a history of deep venous thrombosis, chronic lung disease, and hypertension, are significant predictors of health outcomes, highlighting the need for comprehensive management strategies for PAD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!